Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients

Clinical Cancer Research

Volumn 14, Issue 4, 2008, Pages 1073-1079

  De Bruin, Elza C ^a,b   Van DeVelde, Cornelis J H ^a   Van Krieken, J Han J M ^d   Marijnen, Corrie A M ^a,c   Medema, Jan Paul ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLASS II TRANSACTIVATOR; GAMMA INTERFERON; HLA DR ANTIGEN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL STRAIN HT29; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECTUM CANCER; SURVIVAL TIME; UNIVARIATE ANALYSIS;

BLOTTING, WESTERN; CLINICAL TRIALS AS TOPIC; FEMALE; HLA-DR ANTIGENS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS (GENETICS); RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS;

EID: 39749166991     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1597     Document Type: Article

References (38)